Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 64
• Langue: English

Extrait

Frost & Sullivan Recognizes Sanovas for its

Path-Breaking Innovation in the Treatment of

Pulmonary Disease

PR Newswire

MOUNTAIN VIEW, California, June 12, 2012

- The company's unique Vas Zeppelin catheter-based microsurgery technology

platform combines the strengths of various treatment approaches while

minimizing associated risks

MOUNTAIN VIEW, California

,

June 12, 2012

/PRNewswire/ -- Based on its recent

analysis of the pulmonary disease treatment market, Frost & Sullivan

recognizes Sanovas, Inc. with the 2012 North American Frost & Sullivan Award

for New Product Innovation. Sanovas's pioneering Vas Zeppelin microsurgery

technology platform represents a major leap forward in the tools available to

diagnose and treat lung cancer and other airway obstructions.

The increasing incidence of pulmonary disease has already reached epidemic

proportions. Due to the lack of effective treatment and curative solutions, the

vast majority of treatment costs go toward palliative care services that provide

no chance of recovery and minimal quality-of-life enhancement for patients.

The lack of effective options for this highly under-served patient population

underscores the need for novel and innovative approaches.

"Given the unique anatomical structure of the lungs, most existing treatment

options including surgery, chemotherapy, and radiation come with major trade-

offs," says Venkat Rajan, Frost & Sullivan's industry manager for advanced

medical technologies. "Sanovas is developing tools that are re-imagining what

is possible in a disease where major advances in care over the past decade

have been nominal."

The Vas Zeppelin catheter-based microsurgery platform is a feat in medical

device convergence unlike any other. Typically, a convergent medical device

indicates a two-in-one drug-device combination, diagnostic-treatment tool, or

imaging-intervention product of some variety. However, Sanovas has

developed a platform technology that for the first time offers physicians a

flexible collection of real-time imaging, access, resection, diagnostics, and drug

delivery tools in one therapy enabling system.

"The Vas Zeppelin microsurgical technology platform could be the

breakthrough that significantly alters the existing paradigm," opines Venkat.

"Early detection and intervention could be the key to providing patients

diagnosed with lung cancer a more optimistic prognosis."

Due to its optimal profile and multifaceted construct, the Vas Zeppelin platform

can conceivably address pathology found in small diameter anatomy below 3

millimeters. Altogether, Sanovas has provided an all-in-one solution at a scale

and at dimensions that may very well enable early intervention in small

diameter anatomies that are not currently accessible. The platform combines

the strength of various treatment approaches and minimizes the associated

risks of venturing into the lungs.

The Vas Zeppelin platform's on-board imaging capabilities provide